Author(s): Ribas A, Tumeh PC, Ribas A, Tumeh PC
Abstract Share this page
Abstract It is conceivable that, in the near future, an assay that defines the likelihood of a patient with advanced cancer to respond to immunotherapy based on PD1/L1 blockade will be the initial decision point to select the treatment of patients with any cancer type. ©2014 American Association for Cancer Research.
This article was published in Clin Cancer Res
and referenced in Journal of Oncology Translational Research